For Loeb & Loeb, protecting life sciences innovators through U.S. and international patent litigation and strategic IP counsel is just as key.
Take Switzerland-based Roche, for example, the world’s largest biotech company. For years, Loeb & Loeb has helped this global health care leader safeguard its most valuable assets – its patents.
We’ve advised Roche in complex litigations against several generic drugmakers seeking to sell “at risk” copycat alternatives to Roche’s breakthrough treatments. We also provide IP strategy and due diligence in the licensing and acquisition of pioneering drug products – most recently in Roche’s $8.3 billion strategic acquisition of InterMune, creator of an orphan drug to treat a deadly lung disease.
Our attorneys are also representing life science companies such as Actelion Pharmaceuticals in a number of active inter partes review proceedings. We’ve successfully initiated review of third-party patents and defended the validity of our clients’ patents covering a range of health care technologies and treatments.
It’s no secret that Loeb & Loeb serves as trusted patent counsel to some of the world’s largest and most successful life sciences leaders. What’s lesser known is how active we are in representing early-stage innovators within the industry.
Through close collaboration with our regulatory, corporate and capital markets teams – which are helping many young pharma, biotech and medical device companies obtain critical financing and FDA product approvals – Loeb & Loeb’s patent attorneys help clients build and strengthen their IP portfolios before trouble occurs.
Prudent, early IP counsel is our prescription for life sciences companies at all stages of development.